Phase 1 Sjogren's Syndrome Clinical Trials
9 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–9 of 9 trials
Recruiting
Phase 1
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
Sjogren's SyndromeSjogren DiseaseSjögren
Cullinan Therapeutics Inc.36 enrolled11 locationsNCT07041099
Recruiting
Phase 1
An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Systemic Lupus ErythematosusLupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07236762
Recruiting
Phase 1
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Systemic Lupus Erythematosus (SLE)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled2 locationsNCT07236801
Recruiting
Phase 1
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
Systemic Lupus Erythematosus (SLE)Inflammatory MyopathySystemic Sclerosis (SSc)+2 more
Therorna12 enrolled1 locationNCT07413341
Recruiting
Phase 1Phase 2
Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT
Sjogren's Syndrome
Peking Union Medical College Hospital60 enrolled1 locationNCT07062523
Recruiting
Phase 1Phase 2
Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
LymphomaPrimary Sjogren's Syndrome
Bangdong Gong6 enrolled1 locationNCT06967038
Recruiting
Phase 1Phase 2
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
Systemic Lupus ErythematosusSjogren's SyndromeAutoimmune Diseases+1 more
Essen Biotech60 enrolled1 locationNCT06428188
Recruiting
Phase 1Phase 2
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Systemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisSjogren's Syndrome+6 more
Essen Biotech75 enrolled1 locationNCT06350110
Recruiting
Phase 1
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
DermatomyositisSystemic SclerodermaAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+2 more
Chongqing Precision Biotech Co., Ltd24 enrolled1 locationNCT06056921